Table 3.

Pharmacokinetics of LTX-315 in human plasma.

ArmLTX-315 dose (mg/injection)NCmax (ng/mL)AUC hour*ng/mLTmax (hour)
A2324 ± 2660.08
336 ± 1NR0.03
4395 ± 104280.02
53481 ± 72067 ± 610.02
65427 ± 43249 ± 400.03
74389 ± 402617 ± 330.26
B*3359 ± 2622 ± 190.25
427a20.03
B**34214 ± 260155 ± 1420.68
4221a70.32
52889 ± 10602120.79
  • Note: The different arms including distinct treatment schedules and LTX-315 doses per injection are shown. Cmax is the maximum (or peak) serum concentration of LTX-315 achieved after the drug was administrated. AUC is the integral of the concentration–time curve (after a single dose or in steady state). Tmax is the time to reach Cmax. NR, not reportable, insufficient timepoints with drug concentration above the detectable threshold.

  • aSystemic exposure to LTX-315 was not detectable in one 1 out of 2 patients.